Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542684 | 0.96 | XIAP (0.37) | XIAPNPC1RAB9AADRB3SMN1; SMN2 | |
| SCHEMBL13314796 | 0.96 | XIAP (0.37) | XIAPNPC1RAB9AADRB3SMN1; SMN2 | |
| Formic Acid SCHEMBL3537717 | 0.89 | XIAP (0.38) | XIAPRAB9AADRB3SMN1; SMN2 | |
| Formic Acid SCHEMBL3537527 | 0.86 | GAA (0.35) | XIAPADRB3 | |
| SCHEMBL3541027 | 0.85 | XIAP (0.40) | XIAPNPC1RAB9AADRB3SMN1; SMN2 | |
| SCHEMBL13314795 | 0.85 | XIAP (0.40) | XIAPNPC1RAB9AADRB3SMN1; SMN2 | |
| Formic Acid SCHEMBL3544409 | 0.83 | F2 (0.41) | XIAPNPC1RAB9AADRB3SMN1; SMN2 | |
| SCHEMBL3536340 | 0.82 | GAA (0.37) | XIAPNPC1RAB9AADRB3SMN1; SMN2 | |
| SCHEMBL13314792 | 0.82 | GAA (0.37) | XIAPNPC1RAB9AADRB3SMN1; SMN2 | |
| Formic Acid SCHEMBL3599825 | 0.80 | MAPT (0.31) | XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | XIAP 3138/4885NPC1 3023/4885RAB9A 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.